Insider buying last 90 days
No open-market insider purchases were filed for BLCO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BLCO insider filing, plotted on the chart in Gekko.Open BLCO in Gekko
NYSE: BLCO
Bausch + Lomb (BLCO) Stock Analysis & Forecast
Sep 28 close
$16.95+0.09 (+0.5%)
Gekko Brief
AI summaryThis week brings little company-specific news beyond a routine filing, as former director Karen Ling notified plans to sell 4,500 shares valued at $75,735 stemming from prior restricted stock vestings. Coverage otherwise included a comparative financial survey pitting Bausch + Lomb against Merit Medical Systems, and a note highlighting a 3.1% share rise to $17.32 alongside a GF Score of 77/100 from an outside assessment describing the stock as undervalued relative to its own GF Value benchmark.
BLCO closed at $16.95, essentially flat on the day, with the price sitting between its 50-day average of $17.00 and 200-day average of $16.64, reflecting a mixed trend. The GekkoIndex reads 60.5, placing the stock in the Accumulation zone, though the reading has eased by 3 points over the past five sessions. Against Gekko Fair Value of $14.50, the current price stands 16.9% above that level. The 52-week range spans $13.77 to $18.92, with one-year returns at 18%.
Over the next 20 trading days, no earnings report is expected, with the next date set for 4 November, 36 days out. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though 2 billionaire holders are noted. Seasonally, this calendar stretch has averaged -0.9% over 4 years, with gains in 2 of those years. Analyst coverage from 11 firms shows 5 buy, 5 hold, and 1 sell ratings, with a consensus target of $19.04.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Bausch + Lomb price vs fair value
Close $16.95200-day averageGekko Fair Value $14.50
Bausch + Lomb quick facts
- Market cap
- $6.05B
- P/E ratio
- —
- Forward P/E
- 11.4
- EPS, TTM
- −$0.48
- Revenue, TTM
- $5.32B
- Profit margin
- -3.2%
- Dividend yield
- —
- Beta
- 0.56
- Volume
- 388,511 avg 373,403
- 1-year return
- +18.0%
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.3%
- 50-day average
- $17.00
- 200-day average
- $16.64
- Next earnings
- Nov 4 before open
- Shares outstanding
- 357.2M
Bausch + Lomb swing-trade checklist
Bausch + Lomb scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $16.95 sits between the 50-day ($17.00) and 200-day ($16.64) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.5, Accumulation
Reading 60.5 is in the Accumulation zone.
See the GekkoIndex - Fair valueheadwind
16.9% above
Price is 16.9% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−0.9% on average
From this point in the calendar, the next 20 trading days averaged −0.9% over 4 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bausch + Lomb stock chart and price history
Bausch + Lomb closed at $16.95 on Sep 28, 2026, +18.0% over the past year, inside a 52-week range of $13.77 to $18.92.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.1%
- 3 months
- +1.9%
- 6 months
- +10.3%
- 1 year
- +18.0%
The full BLCO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLCO in Gekko
Follow Bausch + Lomb through every session
Put BLCO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BLCO in GekkoFree for 7 days. No credit card required.
About Bausch + Lomb
Bausch + Lomb focuses on eye health, offering products that range from everyday vision correction to treatments for diseased or post-surgical eyes. The company is widely recognized for its contact lenses, which span daily disposables through longer-wear options, alongside lens care solutions, over-the-counter eye drops and supplements addressing issues like dryness, allergies and conjunctivitis.
The business is divided into three areas. One covers vision care and consumer eye health products. Another, Ophthalmic Pharmaceuticals, develops branded and generic prescription drugs for conditions such as glaucoma, ocular hypertension and retinal disease, along with therapeutic contact lenses used post-surgery. The third, Surgical, supplies equipment for cataract and retinal procedures, including intraocular lenses, delivery systems, phacoemulsification devices and other surgical instruments.
Bausch + Lomb traces its founding back to 1853 and operates out of Vaughan, Canada. Its shares are listed on the NYSE under the ticker BLCO.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- bausch.com
Bausch + Lomb GekkoIndex: the smart money zone
Bausch + Lomb’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.5, in the Accumulation zone, down 3 points over five sessions.
60.5Accumulation
Down 3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +0.1% | +4.1% | ||
| Accumulation (current zone) | 203 | +0.7% | +0.7% | ||
| Neutral | 385 | +0.3% | +1.1% | ||
| Distribution | 41 | −1.1% | −2.1% | ||
| Selling | 6 | Too few readings yet | |||
Average BLCO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the BLCO price, zone by zone.Track BLCO in Gekko
Is Bausch + Lomb stock overvalued? Gekko Fair Value
Bausch + Lomb trades 16.9% above Gekko Fair Value of $14.50, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Bausch + Lomb shares are worth, recalculated every trading day.
$14.50
Gekko Fair Value, Sep 26, 2026
16.9% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BLCO in Gekko
Bausch + Lomb insider and Congress trading
No open-market insider purchases were filed for Bausch + Lomb, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BLCO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BLCO, plotted on the chart in Gekko.Open BLCO in Gekko
Buybacks
Bausch + Lomb has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $27.00M
- As a share of market cap
- 0.45%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold BLCO.
1added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Bausch + Lomb earnings: next date and track record
Bausch + Lomb reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $0.21
- Revenue estimate
- $1.37B
4 of 8reports beat the EPS estimate
±4.1%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 25, 2026 AI summary
- What they said
- Bausch + Lomb reported a strong Q4 and full-year 2025 with record revenue ($1.405B Q4; $5.101B full year) and record adjusted EBITDA ($330M Q4) and improved adjusted EBITDA margin (23.5% in Q4; 17.5% for year). Management emphasized execution from the Vision 27 program, operating leverage, and disciplined investments. The dry eye franchise (Miebo and Xiidra) was highlighted as the primary growth engine — Miebo delivered exceptional prescription growth (113% YoY in 2025) and revenue ($316M for 2025) and management raised its peak-sales expectation for Miebo from $500M to above $600M. Xiidra showed stabilization with modest Rx growth and expected mid-single-digit revenue growth in 2026 driven by net pricing improvements despite slower TRx. Consumer brands (LUMIFY, Blink, PreserVision) and Contact Lens businesses also performed well (contact lenses outpacing the market; Daily SiHy strong growth). Early clinical data for a Halo daily disposable contact lens were encouraging (no adverse events; ~98.5% clear vision in study), supporting a 2028 launch timeline. Management provided details on financial phasing and medium-term targets: 2026 guidance centered on mid-single-digit revenue growth and stronger EBITDA expansion (midpoint implying ~6% top-line, ~15% EBITDA growth), a target 2026 EBITDA margin around 19%, improving gross margin and SG&A leverage, higher R&D (~7.5% of sales), CapEx stepping down to ~5–6% of revenue, and free cash flow conversion improving toward ~45% (50%+ targeted by 2028). Management repeatedly emphasized confidence and execution while acknowledging seasonality, payer dynamics, competitive pressures and operational headwinds (tariffs, recall).
- Guidance
- 2026: Midpoint implies ~6% revenue growth and ~15% adjusted EBITDA growth; 2026 EBITDA margin target ~19%; Q1 typically ~22% of annual revenue; Q1 EBITDA contribution ~18% of midpoint; Xiidra expected mid-single-digit revenue growth in 2026; Miebo peak sales now expected to exceed $600M; CapEx expected ~5–6% of revenue in 2026 (down from ~6–7% in 2025); Free cash flow conversion expected ~45% in 2026 (50%+ target by 2028).
- Risks flagged
- enVista recall and related contract hangover in monofocal IOLs; tariffs (~80 basis points headwind to gross margin in 2025); payer changes/IRA impacts affecting prescriptions and pricing dynamics; competition across pharma, contact lenses and IOLs; macro/consumer softness in some geographies (China, Southeast Asia); seasonality in prescription business (Q1 weaker, Q4 stronger); material float/ownership (BHC-held float) limiting multiple expansion and outside the company's control.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 25, 2026 | $0.32 est $0.36 | $1.41B est $1.39B | +0.3% |
| Oct 29, 2025 | $0.18 est $0.16 | $1.28B est $1.38B | −0.4% |
| Jul 30, 2025 | $0.07 est $0.06 | $1.28B est $1.27B | −7.0% |
| Apr 30, 2025 | −$0.07 est $0.03 | $1.13B est $1.25B | −15.5% |
| Feb 19, 2025 | $0.25 est $0.24 | $1.28B est $1.15B | −2.8% |
| Oct 30, 2024 | $0.13 est $0.16 | $1.20B est $1.25B | −2.3% |
| Jul 31, 2024 | $0.13 est $0.12 | $1.22B est $1.61B | −0.1% |
| May 1, 2024 | $0.07 est $0.07 | $1.10B est $1.62B | −4.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bausch + Lomb stock forecast and analyst price targets
Analysts’ average 12-month price target for Bausch + Lomb is $19.04, +12.3% from the last close, from 11 firms rating the stock in the last 90 days.
$19.04consensus 12-month target, +12.3% from the last close
Now $16.95Avg $19.04
Low $16High $24
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Wells Fargo | $18 | +6.2% |
| Sep 9 | Leerink Partners | $24 | +41.6% |
| Aug 28 | H.C. Wainwright | $21 | +23.9% |
| Aug 25 | Stifel Nicolaus | $16 | −5.6% |
| Aug 13 | Citi | $21 | +23.9% |
+0.7%average 20-day move after past Accumulation readings
−0.9%average move over the next 20 trading days in the last 4 years
±2.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bausch + Lomb seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Bausch + Lomb averaged −0.9% across the last 4 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 3 of 4 |
| Next 10 trading days | −0.9% | 1 of 4 |
| Next 15 trading days | +2.1% | 2 of 4 |
| Next 20 trading days | −0.9% | 2 of 4 |
| Next 30 trading days | +0.9% | 2 of 4 |
For scale, BLCO’s typical 20-trading-day move in either direction is about 5.3%.
Bausch + Lomb market cap and key statistics
Bausch + Lomb’s market cap is $6.05B and revenue of $5.32B over the last twelve months.
Valuation
- Market cap
- $6.05B
- Forward P/E
- 11.4
- EPS, TTM
- −$0.48
- Gekko Fair Value
- $14.50
Trading
- Volume
- 388,511
- Avg volume, 20 days
- 373,403
- 52-week high
- $18.92
- 52-week low
- $13.77
- Shares outstanding
- 357.2M
Financials
- Revenue, TTM
- $5.32B
- Profit margin
- -3.2%
- Return on equity
- -2.5%
- Quarterly earnings growth, YoY
- −88.6%
Risk and income
- Beta
- 0.56
- Typical daily move
- ±2.6%
- Typical 20-day move
- ±5.3%
Bausch + Lomb stock news this week
Coverage of Bausch + Lomb this week reads neutral: 1 positive, 2 neutral and 0 negative headlines.
- Former Bausch & Lomb Director Karen Ling Files Form 144 to Sell 4,500 SharesKalkine Media, Sep 28
- A former director plans to sell 4,500 Bausch & Lomb (BLCO) shares from stock vesting.Stock Titan, Sep 28
- Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)Defense World, Sep 24
- Bausch & Lomb Corp (BLCO) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100GuruFocus, Sep 22
Bausch + Lomb peers
Bausch + Lomb’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Bausch + Lomb stock FAQ
What is Bausch + Lomb’s market cap?
Bausch + Lomb’s market cap is $6.05B at the Sep 28, 2026 close of $16.95, with 357.2M shares outstanding.
What is the Bausch + Lomb stock forecast?
The consensus analyst 12-month price target for Bausch + Lomb is $19.04, +12.3% from the last close. Of the 11 firms that rated the stock in the last 90 days, 5 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Bausch + Lomb stock overvalued or undervalued?
On Gekko’s estimate Bausch + Lomb is overvalued: the Sep 28, 2026 close of $16.95 is 16.9% above Gekko Fair Value of $14.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bausch + Lomb report earnings next?
Bausch + Lomb is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $0.21 per share on revenue of $1.37B. Bausch + Lomb beat the earnings estimate in 4 of its last 8 reports, moving 4.1% on average across the report.
What is Bausch + Lomb’s 52-week high and low?
Bausch + Lomb’s 52-week high is $18.92 and its 52-week low is $13.77; it closed at $16.95 on Sep 28, 2026, +18.0% over the past year. Over the last five years the shares peaked at $21.95 on Jun 30, 2023.
Is Bausch + Lomb stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and earnings risk), 2 as mixed (trend and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bausch + Lomb the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.